GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc disclosed that Maya Martinez-Davis, President, acquired 9.324 notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan account on October 22, 2026, at a reported price of $51.2100 per ADS. The transaction was reported as a single transaction on the New York Stock Exchange.
GSK plc reported interim AZUR-1 results for Jemperli (dostarlimab) monotherapy in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer: 76% of evaluable patients (110/144) achieved a complete response in an exploratory analysis. This included 68% (98/144) with an investigator-assessed clinical complete response sustained for at least 12 months without surgery, plus 12 patients whose complete response was confirmed through tissue analysis after surgery. No disease recurrences have been reported among responders to date after a median follow-up of more than two years.
For the primary endpoint, independent central review data continue to mature: 47% of evaluable patients (54/116) had achieved cCR12 at analysis, while 38 participants with a clinical complete response had not yet reached the 12-month assessment. Serious adverse reactions occurred in 20% of patients; adverse reactions led to permanent discontinuation in 3%. Patients received nine cycles over six months, with a 500 mg intravenous infusion every three weeks. GSK said the data supported Jemperli's recent US approval for this indication.
GSK plc announced updated Phase Ib BEHOLD-1 results for mocertatug rezetecan (Mo-Rez), an investigational B7-H4-targeted antibody-drug conjugate, in platinum-resistant ovarian cancer. At the selected Phase III dose of 5.8 mg/kg, the confirmed objective response rate was 62% (28/45); median duration of response was 12.2 months, and median progression-free survival was 11.1 months, with more than 13 months of follow-up.
Grade ≥3 treatment-related adverse events occurred in 71% (32/45) of patients and were predominantly haematologic. Treatment-related adverse events led to discontinuation in 2% (1/45); interstitial lung disease/pneumonitis occurred in 2% (1/45). Five pivotal Phase III trials are underway across ovarian and endometrial cancers. GSK acquired exclusive worldwide rights from Hansoh Pharma to progress Mo-Rez’s clinical development and commercialisation, excluding mainland China, Hong Kong, Macau and Taiwan.
GSK plc announced that the US FDA approved Hibsago (bepirovirsen) for chronic hepatitis B in adults without cirrhosis who have received nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy for at least 6 months, have suppressed HBV DNA and HBsAg levels ≤3000 IU/ml, and take it in combination with NrtI therapy. The treatment course is six months, with self-administration as an option after the first dose.
Pooled B-WELL phase III results showed a functional cure response in 19% (233 of 1,220), versus 0 of 614 in the placebo group; among participants with HBsAg ≤1000 IU/ml, the response was 26% (200 of 768), versus 0 of 393. Functional cure means HBV DNA and HBsAg remain undetectable for at least 24 weeks after all treatment stops. The most frequently observed adverse events included injection-site erythema, local pain and a temporary rise in a liver enzyme.
GSK plc announced that the FDA approved Jemperli (dostarlimab) under the accelerated approval pathway for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer, making it the first and only immunotherapy approved for this group. In AZUR-1, investigator-assessed results showed sustained clinical complete responses at 12 months in 68% of evaluable patients (98/144; 95% CI: 60%–76%). An exploratory analysis found 76% (110/144; 95% CI: 69%–83%) had no evidence of cancer one year or more after treatment; no recurrences have been reported among responders after median follow-up of more than two years.
Jemperli monotherapy could help eligible patients avoid chemotherapy, radiation and surgery. Serious adverse reactions occurred in 20% of patients, and adverse reactions led to permanent discontinuation in 3%; the most common reactions were fatigue (32%), rash (22%), diarrhoea (18%) and pruritus (17%).
GSK plc reported global phase Ib dose-optimisation results for its investigational B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) in relapsed extensive-stage small cell lung cancer. Among evaluable patients, confirmed objective response rate was 61% at 8 mg/kg (11 of 18; 95% CI: 35.7% to 82.7%) and 32% at 6 mg/kg (7 of 22; 95% CI: 13.9% to 54.9%). GSK said the results, together with data from Hansoh’s phase III ARTEMIS-008 study in SCLC, supported selection of 8 mg/kg for its global phase III EMBOLD SCLC-301 study.
At a median follow-up of 100.5 days, grade 3 or higher treatment-related adverse events were reported in 42% of patients at 8 mg/kg and 15% at 6 mg/kg; haematological events were most common. Interstitial lung disease occurred in 1 of 50 patients (2%) and was grade 2. The analysis included 50 patients who had received a median of two prior therapies. Enrollment in the dose-optimisation portion was ongoing at data cut-off, and longer follow-up will be needed to further characterise response durability. The results will be presented at ESMO Congress 2026.
GSK plc reports that James Ford, SVP and Group General Counsel, Legal and Compliance, acquired 326.441 ADS; Maya Martinez-Davis, President, acquired 351.842 ADS; and Shobie Ramakrishnan, Chief Digital and Technology Officer, acquired 724.875 ADS. Each acquisition was priced at $46.9482 per ADS on October 13, 2026, following reinvestment of dividends paid to shareholders on October 8, 2026. The transactions took place on the New York Stock Exchange.
GSK plc reported dividend reinvestment-related increases in executives’ notional interests on October 12, 2026, following dividends paid to shareholders on October 8, 2026. Under the Deferred Annual Bonus Plan, Chief Executive Officer Luke Miels had an increase of 1,413 ordinary shares; Chief Financial Officer Julie Brown, 1,863; SVP and Group General Counsel, Legal and Compliance James Ford, 783; President, Corporate Development David Redfern, 894; President, Global Supply Chain Regis Simard, 1,103; President, Global Affairs Philip Thomson, 660; CEO, ViiV Healthcare and President, Global Health, GSK Deborah Waterhouse, 987; and Chief Scientific Officer Tony Wood, 1,157. Each was priced at £17.3550. Chief Digital and Technology Officer Shobie Ramakrishnan had a notional-interest increase of 364 ADS at $46.5400. Separately, President Maya Martinez-Davis acquired 179.308 ADS at $46.5400, and Brown acquired 2,409.639 ordinary shares at £17.3550 under the Performance Share Plan, subject to a 2-year holding period.
GSK plc reported dividend-reinvestment acquisitions of ordinary shares and American Depositary Shares by people identified as persons discharging managerial responsibilities or persons closely associated with them.
Ordinary-share transactions were reported at £17.5904 on October 8, 2026, following dividends paid that day. American Depositary Share transactions were reported at $46.5883 on October 9, 2026, following dividends paid on October 8. The ordinary-share transactions list the London Stock Exchange, while the ADS transactions list the New York Stock Exchange.
GSK plc reported acquisitions by its officers and associated persons. On October 8, Chief Executive Officer Luke Miels (3 ordinary shares), President, Europe Lynn Baxter (39), SVP and Group General Counsel, Legal and Compliance James Ford (13), President, Corporate Development David Redfern (80), President, Global Supply Chain Regis Simard (32), President, Global Affairs Philip Thomson (52), CEO, ViiV Healthcare and President, Global Health, GSK Deborah Waterhouse (66), SVP & Company Secretary Victoria Whyte (62), and Neil Falkingham, PCA of Lynn Baxter (64), acquired ordinary shares through dividend reinvestment at £17.5852 per share.
Also on October 8, Victoria Whyte acquired 243 ordinary shares and Iain Whyte, PCA of Victoria Whyte, 1,182, following dividend reinvestment at £17.5904. President Maya Martinez-Davis acquired 10.155 ADS at $47.0200 in her GSK Executive Supplemental Savings Plan account on October 7. On October 9, Chief Financial Officer Julie Brown acquired 14 ordinary shares under GSK’s Share Reward Plan at £17.6539, comprising 7 partnership and 7 matching shares; other participants reported the same terms. Further transactions that day included dividend reinvestments and ISA-held shares at £17.6650.